Tauriga Sciences Inc. Appoints Mr. Christian Bailey to Business Advisory Board

Tauriga logo

CAMBRIDGE, Mass., May 10, 2013 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTCQB:TAUG) today announced the appointment of Mr. Christian Bailey to the Company's Business Advisory Board.

"We are very excited that Christian is joining Tauriga's Business Advisory Board," said TAUG CEO Seth M. Shaw. "We believe that Christian's extensive experience and expertise, gained from building multiple technology and biotechnology companies, will serve as an invaluable asset for Tauriga. In addition, Christian's network of scientific thought leaders and world-class experts will be valuable to the Company as it continues to evaluate opportunities that enhance shareholder value and take the Company to the next level."

"I am delighted to join Tauriga's Business Advisory Board and look forward to working closely with its extraordinary entrepreneurial team," said Mr. Bailey. "I believe Tauriga's relentless execution, combined with its proprietary pipeline of innovative life science technologies, lays a robust foundation for growth."

Christian Bailey is the Founder and CEO of Curated Innovation, which partners with impact investors to directly fund technology challenges that would make a huge impact on a health issue they care passionately about (www.curatedinnovation.org). Previously, he invested in spinouts from MIT and Harvard through incTANK Ventures, a vehicle for its partners' own funds which was the seed investor in Agamatrix, Agrivida, and Ligon Discovery. Mr. Bailey also served as interim CEO at Ligon Discovery, during which time he led strategic deals with Bayer and Bristol-Myers Squibb. Before that, he founded and led two technology companies: Lincoln Group, acquired by GPI; and Akaru, one of the first Software as a Service companies, acquired by NewChannel. Mr. Bailey holds a BA and MA in Economics and Management from the University of Oxford. He completed studies in molecular biology and materials science as a Fellow at the Massachusetts Institute of Technology (MIT).

The main objectives of the Business Advisory Board are to provide management with expertise and advice on strategies for raising capital, evaluating business plans, and advancing the process of graduating the listing to a senior stock exchange. As the Company continues to evaluate potentially lucrative opportunities in the life sciences space, Mr. Bailey's experience and network, especially in the biotechnology sector, will be highly complementary to the management team. The Company is working diligently to build a world-class Business Advisory Board which will ultimately comprise seven highly-qualified members with strong experience in both the financial community and biotechnology sector.

About Tauriga Sciences, Inc.:

Tauriga Sciences, Inc. ("the Company") is a life science holding company that focuses on proprietary biotherapeutics and diagnostics, novel medical devices and consumer healthcare. The mission of the Company is to acquire and build a diversified portfolio of medical technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. The Company's new corporate website can be found at URL address (www.taurigasciences.com).


Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission.

CONTACT: For more information please contact: Mr. Seth M. Shaw Chairman & Chief Executive Officer Tauriga Sciences, Inc. www.taurigasciences.com New York: +1-917-796-9926 Montreal: +1-514-840-3697 Email: sshaw@tauriga.com

Source:Tauriga Sciences Inc